Epidemiology of Cannabis Use Among Middle-Aged and Older Adults in the United States
====================================================================================

* Ofir Livne
* Malka Stohl
* Jodi Gilman
* Terry E. Goldberg
* MM Wall
* Deborah S. Hasin

## ABSTRACT

**Importance** Studies report disproportionate increases in cannabis use among middle-aged (50-64) and older (65+) U.S. adults, groups particularly vulnerable to its adverse effects. However, national data on attitudes towards cannabis use and legalization, as well as prevalences of key cannabis-related behaviors are lacking for these groups.

**Objective** To present national prevalences of past-year any cannabis use, medical use, consumption methods, and other important use-related behaviors, and attitudes toward use, as well as associations of such behaviors and attitudes to cannabis use among U.S. adults ages 50 and older.

**Design** Cross-sectional data from the Health and Retirement Study (HRS) were used to calculate weighted prevalences for all cannabis measures by primary age groups (50-64, ≥65) as well as two specified older age groups (65-74, ≥75) and sex. Associations between sociodemographics and cannabis use were evaluated using multivariable logistic regression.

**Main Outcomes and Measures** Self-reported past-year cannabis use (outcome), consumption methods, medical use and health conditions for which cannabis was used, prescriptions by healthcare providers, current and past perception of acceptability, perceptions of risk, and attitudes toward legalization (exposures). Covariates included sex, race/ethnicity, household income, and employment status.

**Setting and Participants** HRS participants who completed the 2018 cannabis use experimental module (n=1,324).

**Results** Past year cannabis use was reported by 18.5% (SE=2.17) and 5.9% (SE=1.19) of middle-age and older adults, respectively in the U.S. In both groups, a majority of individuals consumed cannabis exclusively by smoking. Approximately 25% of middle-aged adults and 20% of older adults used cannabis for medical purposes, with ∼20% in both groups receiving a prescription or recommendation for medical use from a healthcare provider. Over 75% of individuals in both age groups viewed medical use of cannabis as acceptable, and older adults were more likely to view cannabis as a gateway drug and to support restrictions of cannabis laws.

**Conclusions and Relevance** Cannabis use among both middle-aged and older U.S. adults is higher than previously reported in state- and national-level studies, with many engaging in cannabis behaviors associated with increased harm. Greater public health and clinical efforts are needed for tailored prevention and intervention strategies.

## Introduction

Adults age 50 and older are more vulnerable than younger adults to numerous adverse effects of cannabis use,1 e.g., falls,2 motor vehicle crashes,3 injuries, emergency department visits,4 and declines in physical and cognitive health5–7. Since 2006, cannabis use has increased disproportionately among middle-aged (ages 50-64) and older (ages 65+) U.S. adults,8–12 with past-year use in adults 50 years and older increasing more than 3-fold.12,13 The vulnerability to adverse effects of cannabis use in these age groups suggests the need for greater knowledge about cannabis use behaviors to effectively address important individual and public health challenges.

Several factors may have contributed to the increased prevalence of cannabis use among adults 50 years and older. One is the aging of the Baby Boomer cohort, who had higher adolescent rates of drug use and more tolerant attitudes toward cannabis than previous cohorts.14–19 Additional potential contributors include decreasing perceptions of cannabis as risky20 and growing beliefs in its health benefits21,22 despite limited efficacy.1,23 U.S. cannabis legalization and the creation of commercial markets may also contribute to this trend, with 24 states having legalized cannabis use for recreational purposes and 38 states having legalized it for medical purposes; ∼50% of middle-aged and older adults support medical cannabis laws (MCL) and recreational cannabis laws (RCL).24 As more states enact cannabis laws (CL) and the U.S. population ages,25 the number of middle-aged and older adults consuming cannabis is expected to increase further.12,26 However, existing epidemiological studies of these age groups have not addressed key cannabis behaviors and related measures such as cannabis use for medical purposes (‘medical cannabis use’).27

Extant knowledge about cannabis use in middle-aged and older adults often relies on data from small, non-representative samples28–31 or from the National Survey on Drug Use and Health (NSDUH),8–10,32 which surveys basic measures of cannabis use but fails to capture many potential predictors of harms such as methods of consumption and motivations for use. Additionally, previous studies assessing sociodemographic characteristics of adults aged 50 years and older who use cannabis are either outdated or are based on small and non-representative samples.33 Consequently, many questions about cannabis use among middle-aged and older adults remain unanswered. These include: 1. What are the preferred cannabis products and consumption methods in these age groups? 28–31 2. What are attitudes toward medical cannabis use, the prevalence of medical use, and the specific health conditions for which medical cannabis is being used? Also, to what extent was medical cannabis use prescribed or recommended by a healthcare provider? These questions are particularly important to answer given the risk of interactions between medication and cannabis,34 especially among older populations who frequently engage in polypharmacy.35 3. What are key sociodemographic characteristics of middle-aged and older adults who are at increased risk of cannabis use. Considering the broader societal acceptance of cannabis that may differentially impact sociodemographic subgroups over time,10 research aimed at addressing this question is crucial for developing targeted approaches for screening, risk assessment, and intervention strategies.

The Health and Retirement Study (HRS),36 supported by the National Institute on Aging and the Social Security Administration, conducts national surveys of U.S. adults aged 50 years and over. In 2018, HRS conducted a comprehensive assessment of cannabis use behaviors, offering extensive nationally representative data on cannabis use among middle-aged and older adults in the U.S. This, together with careful sampling of these specific age groups and assessments of key sociodemographic factors relevant to middle-aged and older adults, such as employment and retirement status, and receipt of social security benefits, also make HRS a uniquely informative source of epidemiological data on cannabis use in these understudied age groups. A recent HRS brief report37 noted associations of cannabis use measures with health conditions, opioid use and service utilization in adults 50 years and older. However, while a useful start on addressing the epidemiology of cannabis use in this age group, the study did not report on key cannabis use measures such as methods of consumption or medical use, nor did it examine associations with age-specific sociodemographic measures, such as retirement status. Such information is critical to provide a better understanding of the cannabis landscape as it pertains to middle-aged and older adults. Therefore, using 2018 HRS data, we investigated (1) national prevalences of key cannabis behaviors never reported for adults ages 50 and older, including methods of consumption, medical cannabis use and specific conditions for which cannabis was used, healthcare provider prescription or recommendation for medical cannabis use, and perceptions and attitudes toward cannabis use; (2) whether these cannabis behaviors differed by age groups that had been combined in previous studies, and by sex; and (3) whether certain key sociodemographic characteristics are associated with increased risk of past-year cannabis use.

## Methods

### Data Source

The HRS is a longitudinal, biannual nationally representative health survey of ∼20,000 U.S. adults ages 50+ years. It employs a multi-stage area probability design with geographical stratification and clustering, and oversamples specific demographic groups,38 successfully recruiting and retaining minority participants.39 Core interviews are conducted in-person or by phone. The HRS refreshes its sample with younger cohorts every several years, with the most recent refresh in 2016.The HRS includes occasional specialized experimental modules on specific topics, administered to randomly selected participant subsamples,40 including one on *attitudes toward and use of Cannabis* in 2018. All study participants provided written informed consent, and protocols were approved by the University of Michigan Institutional Review Board. In the current study, we utilized data from de-identified public files, creating an analytic sample comprised of core survey respondents who participated in the 2018 experimental module. Response rates for the core survey were 74%,41 and sampling weights were applied to account for differential probability of selection and non-response.38

### Measures

#### Cannabis behaviors

Participants were assessed for past-year and lifetime cannabis use. Nonresponse on these items was imputed to ‘no use’. Among those who reported lifetime cannabis use, several variables were assessed: (1) Method of consumption (smoking, other than smoking); (4) Cannabis use for the treatment of health problems (‘medical cannabis use’); and (5) Healthcare provider recommendation for medical cannabis (‘healthcare provider involvement’). Participants reporting medical cannabis use were asked about health conditions/symptoms for which they used cannabis; these were categorized into 4 groups: emotional and psychological conditions, neurological and sensory conditions, physical conditions (including cancers/tumors; skin conditions; musculoskeletal system/connective tissue conditions; cardiovascular/blood conditions; allergies; sinusitis/tonsillitis; endocrine conditions, metabolic and nutritional conditions; gastrointestinal conditions; reproductive system conditions), and miscellaneous and other health conditions.

#### Attitudes toward cannabis use

Participants of the 2018 cannabis module, regardless of whether they reported lifetime or past year cannabis use, were asked binary questions about whether they: (1) currently believe that cannabis use for medical reasons is acceptable; (2) believed at age 18 that cannabis use for medical reasons is acceptable; (3) believe cannabis use leads to use of harder drugs (i.e., “gateway drug”); and (3) believe enforcement of cannabis laws should be restricted.

#### Sociodemographic characteristics

These included: sex (male, female); age (2-level variable representing middle-aged and older adults [51-64 years, ≥65 years] and more detailed 3-level variable [51-64 years, 65-74 years, ≥75 years]); race (White, Black or African American, other); ethnicity (Hispanic, non-Hispanic), marital status (married, annulled/separated/divorced, widowed, never married); veteran status (veteran, non-veteran); educational level (less than high school; high school, some college or higher); employment and retirement status (employed, unemployed, retired); annual household income ($0-$19,999, $20,000-$34,999, $35,000-$59,999, ≥$60,000); poverty level (below, above), defined according to yearly U.S. Census poverty thresholds; and receipt of social security benefits.

### Statistical Analysis

Weighted cross-tabulations were used to produce estimated means, prevalences, and standard errors for all cannabis behavior measures within two primary age groups (50-64, ≥65), as well as in two specified older age groups (65-74, ≥75), overall and by sex. Differences in means and prevalences between age groups and between sexes within each age group were evaluated using Wald chi-square tests. Associations between sociodemographic variables and past-year cannabis use were estimated using odds ratios (ORs) obtained from multivariable logistic regressions that controlled for sex, continuous age, race, and educational level. Analyses were performed using SAS 9.4 and SUDAAN version 11.0 to account for the HRS complex sample design.42

## Results

### Sample characteristics

Among HRS participants of the 2018 experimental module on cannabis use behaviors, 54.6% (SE=2.07) were ages 51-64 and 45.4% (SE=2.07) were ages 65+. e-Table 1 presents the sociodemographic characteristics of the analytic sample, overall and by age group

View this table:
[e-Table 1:](http://medrxiv.org/content/early/2024/10/12/2024.10.11.24315329/T4)

e-Table 1: Sample descriptives by age group.

### Cannabis measures by age and sex (Table 1)

View this table:
[Table 1.](http://medrxiv.org/content/early/2024/10/12/2024.10.11.24315329/T1)

Table 1. Prevalence of cannabis use measures by age (51-64, 65+) and by sex.

The prevalence of past-year cannabis use was 18.50% (SE=2.17) among middle-aged adults and 5.87% (SE=1.19) among older adults (p<.0001). Among adults age 65+, prevalences were higher in those age 65-74 (8.84% [SE=2.01]) than in those 75+ (1.78% [SE=0.60]), p<.0001; e-Table 2).

View this table:
[e-Table 2.](http://medrxiv.org/content/early/2024/10/12/2024.10.11.24315329/T5)

e-Table 2. Prevalence of cannabis use measures by age (51-64, 65-74, 75+) and by sex.

Among individuals reporting lifetime cannabis use, 26.10% (SE=3.12) of middle-aged adults and 32.87% (SE=5.03) of older adults consumed cannabis through non-smoking methods (p=0.23).

Among individuals reporting lifetime cannabis use, 25.03% (SE=3.20) of middle-aged adults and 20.45% (SE=4.08) of older adults reported lifetime medical cannabis use (p=0.33). Health conditions for which medical cannabis was used appear in Table 1. Among middle-aged adults, miscellaneous and other conditions (39.29%) were the most commonly reported reasons for medical cannabis use, followed by emotional and psychological conditions (25.97%), physical conditions (20.44%), and neurological and sensory conditions (9.12%). Older adults most commonly reported physical conditions (54.14%) as their reason for medical cannabis use, followed by miscellaneous and other conditions (18.88%), emotional and psychological conditions (16.31%), and neurological and sensory conditions (10.66%). Among medical cannabis users, similar proportions of middle-aged and older adult users received a healthcare provider’s recommendation for medical cannabis (21.98% [SE=4.93] and 20.54% [SE=4.36] respectively (p=0.82).

Few sex differences in cannabis behaviors were found. Among middle-aged adults, the prevalence of past-year cannabis use was nearly three times higher in males than in females (males: 27.60% [SE=4.11]; females: 10.05% [SE=2.21], p<.01). Among older adults, the prevalence of cannabis consumption through non-smoking methods was twice as high in females compared to males (males: 22.45% [SE=5.37]; females: 45.26% [SE=7.02], P<.05).

### Attitudes toward cannabis by age and sex (Table 2)

View this table:
[Table 2.](http://medrxiv.org/content/early/2024/10/12/2024.10.11.24315329/T2)

Table 2. Attitudes towards cannabis use by age (51-64, 65+) and by sex.

In 2018, 89.12% (SE=1.76) of middle-aged adults and 77.19% (SE=2.44) of older adults viewed medical cannabis use as acceptable (p<.0001). At age 18, 39.74% (SE=2.68) of middle-aged adults and 13.84% (SE=1.86) of older adults viewed medical cannabis use as acceptable (p<.0001). Older adults were significantly more likely than middle-aged adults to view cannabis as a gateway drug (51-64: 41.59% [SE=3.00]; 65+: 71.18% [SE=2.12], P<.0001). e-Table 3 shows additional information about attitudes toward cannabis among those ages 65-74 and 75+. With few exceptions, no significant sex differences were observed in attitudes toward cannabis in either age group.

View this table:
[e-Table 3.](http://medrxiv.org/content/early/2024/10/12/2024.10.11.24315329/T6)

e-Table 3. Attitudes towards cannabis use by age (51-64, 65-74. 75+) and by sex.

### Sociodemographic variables (Table 3)

View this table:
[Table 3.](http://medrxiv.org/content/early/2024/10/12/2024.10.11.24315329/T3)

Table 3. Associations between sociodemographic variables and past-year cannabis use among adults ages 50-64 and 65+.

There were no differences by sociodemographic characteristics in either age group except for sex differences in past-year cannabis use among middle-aged adults.

## Discussion

In 2018, 18.5% of U.S. adults aged 50–64 and 5.9% of U.S. adults aged 65 and older used cannabis, representing over 11.5 million and 3 million individuals, respectively.43 In addition to revealing higher numbers of U.S. middle-aged and older adults with past-year cannabis than previously reported in national surveys, this is the first nationally-representative epidemiological study to report the prevalences of key cannabis use behaviors in these age groups, including medical cannabis use for specific health conditions healthcare provider prescriptions. This study’s findings also highlight that a significant portion of users from these vulnerable age groups are engaging in cannabis behaviors associated with increased harm, such as smoking as a primary method of consumption.

The prevalence of cannabis use among U.S. middle-aged and older adult HRS participants is markedly higher than reported by NSDUH participants from similar age groups in corresponding years.44,45 While both surveys employ a multistage area probability sample design, HRS oversamples adults age 65+ from minority groups and certain selected geographic areas, whereas NSDUH focuses on broad national and state-level representation. Furthermore, HRS uses clustering and stratification variables to account for the geographic clustering of its sample, which is less emphasized in NSDUH. This enhances HRS’s variance estimates for its older adult population.46,47 Consequently, HRS’s probability sampling method likely offers considerable accuracy in representing middle-aged and older adults nationally.

This study separated older adults into two groups, ages 65-74 and 75+, which were combined in previous NSDUH and HRS reports, potentially overlooking cannabis behaviors and sociodemographics unique to each group. Past-year cannabis use was nearly five times higher in adults 65-74 than in those 75+, xxxx. These rising rates among these older individuals warrant clinician awareness of their increased risk of harm, driven by aging-related physiological changes such as altered drug metabolism and neurotransmitter sensitivity.48–50

In 2018, middle-aged males were nearly three times more likely to use cannabis than females, aligning with other national- and state-level reports. No sex differences were observed in the older adult age group, suggesting that the previously reported gender gap in cannabis use among older adults33 may be narrowing, possibly due to disproportionate increases in cannabis use among women,10 particularly for medical purposes.51–55 This narrowing gap, coupled with a faster progression to problematic use (i.e., “telescoping effect”)56,57 and a lower likelihood of seeking treatment among women,58 indicates a need for prevention and treatment strategies tailored to middle-aged and older adult women.

Approximately one-quarter of middle-aged and one-third of older adults reported consuming cannabis through methods other than smoking, marking the first national epidemiological report on consumption methods among these populations. This finding contrasts with data from Washington State, which indicates a broader variety of consumption methods within these populations.55,59 Such differences may be attributable to easier access to diverse products in states that were early to legislate MCL and RCL, such as Washington. The high rates of cannabis consumption exclusively by smoking among middle-aged and older adults—despite smoking not being the recommended method for medical use underscore their resistance to changing established habits and their continued exposure to smoking-related harms. Notably, our findings suggest that compared to older adult males, older females may be more responsive to public health messaging about using cannabis through less harmful methods. Physicians prescribing cannabis should be aware of such age- and sex-specific cannabis use behaviors, educate patients about the potential harms of smoking, and promote safer medical alternatives for medical cannabis use.

Our findings provide valuable insights into attitudes toward medical cannabis use, its prevalence, and healthcare provider involvement among middle-aged and older U.S. adults—populations increasingly using cannabis to manage chronic conditions.60–63 Approximately 25% of middle-aged adults and 20% of older adults who reported lifetime cannabis use have used it for medical purposes, aligning with smaller studies.64 However, unlike those studies, we did not observe sex differences in medical cannabis use. Unlike NSDUH surveys, which focus on healthcare provider recommendations as a proxy for medical cannabis use, HRS directly assessed it by asking participants about cannabis use for the treatment of physical and mental health problems, including specific conditions, thus providing more accurate estimates of medical use prevalences in the U.S. Among older adults, the prevalence of medical cannabis use decreased with age, mirroring the overall age-related differences in overall (both medical and non-medical) cannabis use.

Our study reveals widespread acceptance of medical cannabis across both age groups, consistent with Pew Research and smaller studies. This acceptance has grown substantially from age 18 to the present, reflecting the increasing belief in cannabis’s therapeutic benefits, possibly influenced by industry marketing efforts, 65,66 and suggesting an expected rise in medical cannabis use among these age groups in the future. These high rates of medical cannabis use among middle-aged and older adults are concerning, given the associated risks, including a 20-25% prevalence of CUD among medical cannabis users, surpassing that of recreational users.67,68 Older adults with chronic conditions, such as chronic pain, are particularly at risk of CUD. 69,70 As rates of medical cannabis use rise, ongoing research is needed to monitor CUD prevalence. Notably, only ∼20% of individuals with medical cannabis use in both age groups received a recommendation from a healthcare provider for cannabis to treat health conditions, indicating widespread self-medication. This practice poses risks of incorrect dosing and dangerous drug interactions. These results may reflect the growing reliance on internet and social media for information about medical cannabis use.71 Stigma or legal concerns may also contribute to this. While healthcare providers generally support medical cannabis use, their knowledge of its administration and legal frameworks varies, leading to mixed views on effectiveness. 72,73 In the absence of evidence-based guidelines, it is vital to improve education for both patients and physician, ensure access to knowledgeable providers, and engage policymakers in developing harm prevention strategies for safer use.

Older adults are more likely than middle-aged adults to view cannabis as a gateway drug, with nearly three-quarters believing it leads to the use of harder substances. This contrasts with NSDUH data, where less than half of older adults perceive cannabis as a risky.20 Differences in methodology, such as NSDUH’s broader questions on perceived harm versus HRS’s focus on progression to harder substances, may account for this variation. Nonetheless, older Americans perceive cannabis as more harmful than middle-aged adults. Additionally, most older adults support restrictions on cannabis legalization, consistent with Gallup polls.74 Further research is needed to explore whether the risk of cannabis use among older adults varies by legalization status.

This study has several limitations. First, the 2018 experimental module on cannabis use behaviors was only administered once, preventing the assessment of trends in cannabis use behaviors over time. Second, all data are self-reported, which may introduce recall and social desirability biases. third, HRS did not assess other important measures of cannabis use, such as amount of use and product type (e.g., cannabidiol), or outcomes such as CUD. Additionally, medical cannabis use for chronic pain, an increasingly common reason for use, was not specifically assessed in HRS, limiting insights into its prevalence among these age groups. However, HRS has key strengths40 that mitigate these limitations, including a large, nationally representative sample of U.S. adults 50 years and older, allowing for accurate estimates of cannabis use in understudied age groups. The study also employs oversampling and targeted recruitment, resulting in response rates for minorities that are roughly equivalent to those of White individuals, and a high overall panel response rate. Furthermore, it includes a significantly broader range of cannabis measures than other national studies.

## Conclusion

Amid growing belief in the health benefits of cannabis, diminishing risk perceptions, and evolving legislation, middle-aged and older adults emerge as distinct groups warranting special attention due to their growing use of cannabis and engagement in cannabis behaviors that are associated with increased harm. Epidemiological studies such as the current study are vital to understanding the diverse profiles of middle-aged and older adult cannabis users, paving the way for targeted prevention, treatment, and policy initiatives tailored to these rapidly growing and vulnerable populations.

## Data Availability

All data produced are available online at: [https://hrsdata.isr.umich.edu/data-products/hrs-2018-core-module-4-attitude-toward-and-use-marijuana-cannabis-older-americans](https://hrsdata.isr.umich.edu/data-products/hrs-2018-core-module-4-attitude-toward-and-use-marijuana-cannabis-older-americans)

[https://hrsdata.isr.umich.edu/data-products/hrs-2018-core-module-4-attitude-toward-and-use-marijuana-cannabis-older-americans](https://hrsdata.isr.umich.edu/data-products/hrs-2018-core-module-4-attitude-toward-and-use-marijuana-cannabis-older-americans) 

*   Received October 11, 2024.
*   Revision received October 11, 2024.
*   Accepted October 12, 2024.


*   © 2024, Posted by Cold Spring Harbor Laboratory

The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.

## REFERENCES

1.  1.Minerbi A, Häuser W, Fitzcharles MA. Medical Cannabis for Older Patients. Drugs Aging. 2019;36(1):39–51. doi:10.1007/s40266-018-0616-5
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s40266-018-0616-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

2.  2.Workman CD, Fietsam AC, Sosnoff J, Rudroff T. Increased likelihood of falling in older cannabis users vs. Non-users. Brain Sci. 2021;11(2):1–12. doi:10.3390/brainsci11020134
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/brainsci11020134&link_type=DOI) 

3.  3.Johnson MB, Mechtler L, Ali B, Swedler D, Kelley-Baker T. Cannabis and crash risk among older drivers. Accid Anal Prev. 2021;152. doi:10.1016/j.aap.2021.105987
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.aap.2021.105987&link_type=DOI) 

4.  4.Choi NG, Marti CN, DiNitto DM, Choi BY. Older adults’ marijuana use, injuries, and emergency department visits. American Journal of Drug and Alcohol Abuse. 2018;44(2):215–223. doi:10.1080/00952990.2017.1318891
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/00952990.2017.1318891&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

5.  5.Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study. Journal of the International Neuropsychological Society. 2003;9(5):679–689. doi:10.1017/S1355617703950016
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1017/S1355617703950016&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12901774&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000183750400001&link_type=ISI) 

6.  6.Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. Exp Clin Psychopharmacol. 2012;20(5):420–429. doi:10.1037/a0029117
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1037/a0029117&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22731735&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

7.  7.Kurtzman ET, Maritza Dowling N, Beebe SL. Marijuana Use and Older Adults’ Self-Reported Difficulty Concentrating, Remembering, or Making Decisions. J Stud Alcohol Drugs. 2022;83(6). doi:10.15288/jsad.21-00318
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.15288/jsad.21-00318&link_type=DOI) 

8.  8.Salas-Wright CP, Vaughn MG, Cummings-Vaughn LA, et al. Trends and correlates of marijuana use among late middle-aged and older adults in the United States, 2002–2014. Drug Alcohol Depend. 2017;171:97-106. doi:10.1016/j.drugalcdep.2016.11.031
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugalcdep.2016.11.031&link_type=DOI) 

9.  9.Azofeifa A, Mattson ME, Schauer G, McAfee T, Grant A, Lyerla R. National estimates of marijuana use and related indicators - National Survey on Drug Use and Health, United States, 2002-2014. MMWR Surveillance Summaries. 2016;65(11):1-25. doi:10.15585/mmwr.ss6511a1
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.15585/mmwr.ss6506a1&link_type=DOI) 

10. 10.Han BH, Palamar JJ. Trends in Cannabis Use among Older Adults in the United States, 2015-2018. JAMA Intern Med. 2020;180(4):609-611. doi:10.1001/jamainternmed.2019.7517
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamainternmed.2019.7517&link_type=DOI) 

11. 11.Maxwell CJ, Jesdale BM, Lapane KL. Recent Trends in Cannabis Use in Older Americans. Ann Intern Med. 2021;174(1):133–135. doi:10.7326/M20-0863
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7326/M20-0863&link_type=DOI) 

12. 12.Han BH, Sherman S, Mauro PM, et al. Demographic trends among older cannabis users in the United States, 2006-13. Addiction. 2017;112(3):516-525. doi:10.1111/add.13670
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/add.13670&link_type=DOI) 

13. 13.2020 NSDUH Detailed Tables. Available from: [https://www.Samhsa.Gov/Data/Report/2020-Nsduh-Detailed-Tables](https://www.Samhsa.Gov/Data/Report/2020-Nsduh-Detailed-Tables) [Last Accessed: January 21, 2024].
    
    

14. 14.Johnson RA, Gerstein DR. Initiation of use of alcohol, cigarettes, marijuana, cocaine, and other substances in US birth cohorts since 1919. Am J Public Health. 1998;88(1):27–33. doi:10.2105/AJPH.88.1.27
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2105/AJPH.88.1.27&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9584029&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000073804800005&link_type=ISI) 

15. 15.Wu LT, Blazer DG. Substance use disorders and psychiatric comorbidity in mid and later life: A review. Int J Epidemiol. 2014;43(2):304–317. doi:10.1093/ije/dyt173
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ije/dyt173&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24163278&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

16. 16.Lau N, Sales P, Averill S, Murphy F, Sato SO, Murphy S. A safer alternative: Cannabis substitution as harm reduction. Drug Alcohol Rev. 2015;34(6):654–659. doi:10.1111/dar.12275
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/dar.12275&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25919477&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

17. 17.Black P, Joseph LJ. Still Dazed and Confused: Midlife Marijuana Use by the Baby Boom Generation. Deviant Behav. 2014;35(10):822–841. doi:10.1080/01639625.2014.889994
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/01639625.2014.889994&link_type=DOI) 

18. 18.Lloyd SL, Striley CW. Marijuana Use Among Adults 50 Years or Older in the 21st Century. Gerontol Geriatr Med. 2018;4:233372141878166. doi:10.1177/2333721418781668
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1177/2333721418781668&link_type=DOI) 

19. 19.Johnston LD, Miech RA, O’malley PM, Bachman JG, Schulenberg JE, Patrick ME. Sponsored by The National Institute on Drug Abuse at The National Institutes of Health.; 1975.
    
    

20. 20.Han BH, Funk-White M, Ko R, Al-Rousan T, Palamar JJ. Decreasing perceived risk associated with regular cannabis use among older adults in the United States from 2015 to 2019. J Am Geriatr Soc. Published online 2021. doi:10.1111/jgs.17213
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/jgs.17213&link_type=DOI) 

21. 21.Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use. International Journal of Drug Policy. 2013;24(6):511–516. doi:10.1016/j.drugpo.2013.08.010
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugpo.2013.08.010&link_type=DOI) 

22. 22.Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136(1):162–165. doi:10.1016/j.drugalcdep.2013.12.008
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugalcdep.2013.12.008&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24412475&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

23. 23.Solomon H V., Greenstein AP, Delisi LE. Cannabis Use in Older Adults: A Perspective. Harv Rev Psychiatry. 2021;29(3):225–233. doi:10.1097/HRP.0000000000000289
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/HRP.0000000000000289&link_type=DOI) 

24. 24.Overwhelming support for legal recreational or medical marijuana in U.S. | Pew Research Center. Accessed January 20, 2024. [https://www.pewresearch.org/short-reads/2022/11/22/americans-overwhelmingly-say-marijuana-should-be-legal-for-medical-or-recreational-use/](https://www.pewresearch.org/short-reads/2022/11/22/americans-overwhelmingly-say-marijuana-should-be-legal-for-medical-or-recreational-use/)
    
    

25. 25.U.S. Census Bureau. Population Projections.
    
    

26. 26.Colliver JD, Compton WM, Gfroerer JC, Condon T. Projecting drug use among aging baby boomers in 2020. Ann Epidemiol. 2006;16(4):257–265. doi:10.1016/j.annepidem.2005.08.003
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.annepidem.2005.08.003&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16275134&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000236424400003&link_type=ISI) 

27. 27.Wolfe D, Corace K, Butler C, et al. Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature. PLoS One. 2023;18(2 February). doi:10.1371/journal.pone.0281826
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0281826&link_type=DOI) 

28. 28.Ueno LF, Mian MN, Altman BR, Giandelone E, Luce M, Earleywine M. Age-Related Differences in Cannabis Product Use. J Psychoactive Drugs. Published online 2021. doi:10.1080/02791072.2020.1870778
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/02791072.2020.1870778&link_type=DOI) 

29. 29.Levy J. Which cannabis products are popular among different age groups? 2020. Accessed January 14, 2022. [https://www.vcstar.com/story/sponsor-story/hpc-port-hueneme/2020/09/22/which-cannabis-products-popular-among-different-age-groups/5825462002/](https://www.vcstar.com/story/sponsor-story/hpc-port-hueneme/2020/09/22/which-cannabis-products-popular-among-different-age-groups/5825462002/)
    
    

30. 30.Kaufmann CN, Kim A, Miyoshi M, Han BH. Patterns of Medical Cannabis Use Among Older Adults from a Cannabis Dispensary in New York State. Cannabis Cannabinoid Res. Published online November 5, 2020. doi:10.1089/can.2020.0064
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/can.2020.0064&link_type=DOI) 

31. 31.Kaufmann CN, Kim A, Miyoshi M, Han BH. Patterns of Medical Cannabis Use Among Older Adults from a Cannabis Dispensary in New York State. Cannabis Cannabinoid Res. 2022;7(2):224–230. doi:10.1089/can.2020.0064
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/can.2020.0064&link_type=DOI) 

32. 32.Han BH, Palamar JJ. Marijuana use by middle-aged and older adults in the United States, 2015–2016. Drug Alcohol Depend. 2018;191:374-381. doi:10.1016/j.drugalcdep.2018.07.006
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugalcdep.2018.07.006&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

33. 33.Yang KH, Satybaldiyeva MPH N, Bergstrom JM, et al. Sociodemographic and health correlates of cannabis use among middle-aged and older adults: Findings from NESARC-III. J Am Geriatr Soc. Published online February 16, 2024. doi:10.1111/JGS.18800
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/JGS.18800&link_type=DOI) 

34. 34.Qian Y, Gurley BJ, Markowitz JS. The Potential for Pharmacokinetic Interactions between Cannabis Products and Conventional Medications. J Clin Psychopharmacol. 2019;39(5). doi:10.1097/JCP.0000000000001089
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/JCP.0000000000001089&link_type=DOI) 

35. 35.Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4). doi:10.1001/jamainternmed.2015.8581
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamainternmed.2015.8581&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26998708&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

36. 36.Produced and distributed by the University of Michigan with funding from the National Institute on Aging (grant number NIA U01AG009740). Ann Arbor M. Health and Retirement Study, public use dataset. Published online 2020.
    
    

37. 37.Kaskie B, Bhagianadh D, Bobitt J, Martinos F, Milavetz G, Arora K. Unrelenting Growth and Diversification: Using the Health and Retirement Study to Illuminate Cannabis Use among Aging Americans. Gerontologist. Published online February 24, 2024. doi:10.1093/GERONT/GNAE016
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/GERONT/GNAE016&link_type=DOI) 

38. 38.Heeringa SG, Connor JH. Technical Description of the Health and Retirement Survey Sample Design TECHNICAL DESCRIPTION HEALTH AND RETIREMENT STUDY SAMPLE DESIGN. Published online 1995.
    
    

39. 39.Ofstedal MB, Weir DR. Recruitment and retention of minority participants in the health and retirement study. Gerontologist. 2011;51 Suppl 1(Suppl 1). doi:10.1093/GERONT/GNQ100
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/GERONT/GNQ100&link_type=DOI) 

40. 40.Sonnega A, Faul JD, Ofstedal MB, Langa KM, Phillips JWR, Weir DR. Cohort profile: The Health and Retirement Study (HRS). Int J Epidemiol. 2014;43(2). doi:10.1093/ije/dyu067
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ije/dyu067&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24671021&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000335919500027&link_type=ISI) 

41. 41.HRS Staff. HRS Core Interview Sample Sizes and Response Rates. Ann Arbor, MI: Survey Research Center, Institute for Social Research, University of Michigan. 2023. Accessed August 29, 2023. [https://hrs.isr.umich.edu/documentation/survey-design/response-rates](https://hrs.isr.umich.edu/documentation/survey-design/response-rates)
    
    

42. 42.Research Triangle Institute. Release 11. Vol 1 and 2. Research Triangle Park NRTI 2012. SLManual. SUDAAN® Statistical Software for Analyzing Correlated Data. Accessed November 27, 2017. [https://www.rti.org/impact/sudaan-statistical-software-analyzing-correlated-data](https://www.rti.org/impact/sudaan-statistical-software-analyzing-correlated-data)
    
    

43. 43.2018 population age - Census Bureau Tables. Accessed September 13, 2024. [https://data.census.gov/table?q=2018%20population%20age](https://data.census.gov/table?q=2018%20population%20age)
    
    

44. 44.2018 NSDUH Detailed Tables | CBHSQ Data. Accessed July 7, 2024. [https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables](https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables)
    
    

45. 45.Section 1 PE Tables – Results from the 2020 National Survey on Drug Use and Health: Detailed Tables, SAMHSA, CBHSQ. Accessed July 7, 2024. [https://www.samhsa.gov/data/sites/default/files/reports/rpt35323/NSDUHDetailedTabs2020v25/NSDUHDetailedTabs2020v25/NSDUHDetTabsSect1pe2020.htm](https://www.samhsa.gov/data/sites/default/files/reports/rpt35323/NSDUHDetailedTabs2020v25/NSDUHDetailedTabs2020v25/NSDUHDetTabsSect1pe2020.htm)
    
    

46. 46. Beth Ofstedal  David Weir  Kuang-Tsung Chen James Wagner MR. HRS Documentation Report Updates to HRS Sample Weights. Published online 2011. Accessed July 7, 2024. [http://bpp.wharton.upenn.edu/betseys/papers/Inaccurate%20Age%20and%20Sex%20Data%20in%20Census%20PU](http://bpp.wharton.upenn.edu/betseys/papers/Inaccurate%20Age%20and%20Sex%20Data%20in%20Census%20PU)
    
    

47. 47.Ofstedal MB, Weir DR. Recruitment and retention of minority participants in the health and retirement study. Gerontologist. 2011;51 Suppl 1(Suppl 1). doi:10.1093/GERONT/GNQ100
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/GERONT/GNQ100&link_type=DOI) 

48. 48.Ahmed AIA, van den Elsen GAH, Colbers A, et al. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. Eur Neuropsychopharmacol. 2014;24(9):1475–1482. doi:10.1016/J.EURONEURO.2014.06.007
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.euroneuro.2014.06.007&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25035121&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

49. 49.Dowling GJ, Weiss SRB, Condon TP. Drugs of abuse and the aging brain. Neuropsychopharmacology. 2008;33(2):209–218. doi:10.1038/sj.npp.1301412
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/sj.npp.1301412&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=17406645&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000251538100001&link_type=ISI) 

50. 50.Anderson GD, Chan LN. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clin Pharmacokinet. 2016;55(11). doi:10.1007/s40262-016-0400-9
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s40262-016-0400-9&link_type=DOI) 

51. 51.Ryan-Ibarra S, Induni M, Ewing D. Prevalence of medical marijuana use in California, 2012. Drug Alcohol Rev. 2015;34(2):141-146. doi:10.1111/DAR.12207
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/DAR.12207&link_type=DOI) 

52. 52.Aggarwal SK, Carter GT, Sullivan M, ZumBrunnen C, Morrill R, Mayer JD. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag. 2009;5(5):257–286. doi:10.5055/JOM.2009.0028
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.5055/JOM.2009.0028&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19947069&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

53. 53.Cooper ZD, Craft RM. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. Neuropsychopharmacology. 2018;43(1). doi:10.1038/npp.2017.140
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/npp.2017.140&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

54. 54.Bruce D, Grove TJ, Foster E, Shattell M. Gender Differences in Medical Cannabis Use: Symptoms Treated, Physician Support for Use, and Prescription Medication Discontinuation. [https://home.liebertpub.com/jwh](https://home.liebertpub.com/jwh). 2021;30(6):857-863. doi:10.1089/JWH.2020.8437
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/JWH.2020.8437&link_type=DOI) 

55. 55.Cuttler C, Mischley LK, Sexton M. Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users. Cannabis Cannabinoid Res. 2016;1(1):166–175. doi:10.1089/can.2016.0010
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/can.2016.0010&link_type=DOI) 

56. 56.Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74(3):265–272. doi:10.1016/j.drugalcdep.2004.02.001
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugalcdep.2004.02.001&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15194204&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000222127500005&link_type=ISI) 

57. 57.Ehlers CL, Gizer IR, Vieten C, et al. Cannabis dependence in the San Francisco Family Study: Age of onset of use, DSM-IV symptoms, withdrawal, and heritability. Addictive Behaviors. 2010;35(2):102–110. doi:10.1016/j.addbeh.2009.09.009
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.addbeh.2009.09.009&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19818563&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

58. 58.Substance Abuse and Mental Health Services Administration (2014b)). The TEDS Report: Gender Differences in Primary Substance of Abuse across Age Groups.
    
    

59. 59.Subbaraman MS, Kerr WC. Cannabis use frequency, route of administration, and co-use with alcohol among older adults in Washington state. J Cannabis Res. 2021;3(1):1–10. doi:10.1186/s42238-021-00071-3
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s42238-021-00071-3&link_type=DOI) 

60. 60.Briscoe J, Casarett D. Medical Marijuana Use in Older Adults. J Am Geriatr Soc. 2018;66(5):859–863. doi:10.1111/jgs.15346
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/jgs.15346&link_type=DOI) 

61. 61.Minerbi A, Häuser W, Fitzcharles MA. Medical Cannabis for Older Patients. Drugs Aging. 2019;36(1):39–51. doi:10.1007/s40266-018-0616-5
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s40266-018-0616-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F10%2F12%2F2024.10.11.24315329.atom) 

62. 62.MacNair L, Kalaba M, Peters EN, et al. Medical cannabis authorization patterns, safety, and associated effects in older adults. J Cannabis Res. 2022;4(1). doi:10.1186/s42238-022-00158-5
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s42238-022-00158-5&link_type=DOI) 

63. 63.Yang KH, Kaufmann CN, Nafsu R, et al. Cannabis: An Emerging Treatment for Common Symptoms in Older Adults. J Am Geriatr Soc. 2021;69(1):91–97. doi:10.1111/jgs.16833
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/jgs.16833&link_type=DOI) 

64. 64.Livne O, Potter KW, Schuster RM, Gilman JM. Longitudinal Associations Between Cannabis Use and Cognitive Impairment in a Clinical Sample of Middle-Aged Adults Using Cannabis for Medical Symptoms. Cannabis Cannabinoid Res. Published online 2023. doi:10.1089/can.2022.0310
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/can.2022.0310&link_type=DOI) 

65. 65.Hall W. Minimizing the adverse public health effects of cannabis legalization. CMAJ: Canadian Medical Association Journal. 2018;190(35):E1031. doi:10.1503/CMAJ.181035
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1503/CMAJ.181035&link_type=DOI) 

66. 66.Haney M. Perspectives on Cannabis Research—Barriers and Recommendations. JAMA Psychiatry. 2020;77(10):994–995. doi:10.1001/JAMAPSYCHIATRY.2020.1032
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/JAMAPSYCHIATRY.2020.1032&link_type=DOI) 

67. 67.Dawson D, Stjepanović D, Lorenzetti V, Cheung C, Hall W, Leung J. The prevalence of cannabis use disorders in people who use medicinal cannabis: A systematic review and meta-analysis. Drug Alcohol Depend. 2024;257. doi:10.1016/j.drugalcdep.2024.111263
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.drugalcdep.2024.111263&link_type=DOI) 

68. 68.Gilman JM, Schuster RM, Potter KW, et al. Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(3):e222106–e222106. doi:10.1001/JAMANETWORKOPEN.2022.2106
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/JAMANETWORKOPEN.2022.2106&link_type=DOI) 

69. 69.Hasin DS, Wall MM, Alschuler DM, et al. Chronic pain, cannabis legalisation, and cannabis use disorder among patients in the US Veterans Health Administration system, 2005 to 2019: a repeated, cross-sectional study. Lancet Psychiatry. 2023;10(11):877-886. doi:10.1016/S2215-0366(23)00268-7
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2215-0366(23)00268-7&link_type=DOI) 

70. 70.Gilman J. A potential downside of cannabis legalisation for older adults with pain. Lancet Psychiatry. 2023;10(11). doi:10.1016/S2215-0366(23)00304-8
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2215-0366(23)00304-8&link_type=DOI) 

71. 71.Boehnke KF, Litinas E, Worthing B, Conine L, Kruger DJ. Communication between healthcare providers and medical cannabis patients regarding referral and medication substitution. J Cannabis Res. 2021;3(1). doi:10.1186/s42238-021-00058-0
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s42238-021-00058-0&link_type=DOI) 

72. 72.Sideris A, Khan F, Boltunova A, Cuff G, Gharibo C, Doan L V. New York Physicians’ Perspectives and Knowledge of the State Medical Marijuana Program. Cannabis Cannabinoid Res. 2018;3(1). doi:10.1089/can.2017.0046
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1089/can.2017.0046&link_type=DOI) 

73. 73.Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LM. Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - A systematic review. PLoS One. 2019;14(5). doi:10.1371/JOURNAL.PONE.0216556
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/JOURNAL.PONE.0216556&link_type=DOI) 

74. 74.For First Time, Americans Favor Legalizing Marijuana. Accessed July 3, 2024. [https://news.gallup.com/poll/165539/first-time-americans-favor-legalizing-marijuana.aspx](https://news.gallup.com/poll/165539/first-time-americans-favor-legalizing-marijuana.aspx)